This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Leadiant faces Dutch supply-restriction questions over orphan drug's ingredients

By Matthew Newman ( May 7, 2019, 11:31 GMT | Insight) -- Drugmaker Leadiant Biosciences faces questions over whether it is restricting the supply of raw materials for a rare-disease drug as part of a broader Dutch probe into excessive pricing for that treatment. Restricting ingredient supply could limit pharmacists’ ability to blend their own version of the drug. EU rules allow pharmacists to make such “magistral preparations” when there is a lack of alternatives on the market.Drugmaker Leadiant Biosciences faces questions over whether it is restricting the supply of raw materials for a rare-disease drug as part of a broader Dutch probe into excessive pricing for that treatment....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections